MBX vs. BCT, HBP, AEZS, APS, TH, RVX, ATE, SVA, ONC, and MDP
Should you be buying Microbix Biosystems stock or one of its competitors? The main competitors of Microbix Biosystems include BriaCell Therapeutics (BCT), Helix BioPharma (HBP), Aeterna Zentaris (AEZS), Aptose Biosciences (APS), Theratechnologies (TH), Resverlogix (RVX), Antibe Therapeutics (ATE), Sernova (SVA), Oncolytics Biotech (ONC), and Medexus Pharmaceuticals (MDP). These companies are all part of the "medical" sector.
BriaCell Therapeutics (TSE:BCT) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.
Microbix Biosystems has a net margin of 16.57% compared to Microbix Biosystems' net margin of 0.00%. BriaCell Therapeutics' return on equity of 14.66% beat Microbix Biosystems' return on equity.
Microbix Biosystems received 69 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 70.71% of users gave Microbix Biosystems an outperform vote.
13.9% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Microbix Biosystems shares are owned by institutional investors. 12.3% of BriaCell Therapeutics shares are owned by company insiders. Comparatively, 14.4% of Microbix Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
BriaCell Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Microbix Biosystems has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.
Microbix Biosystems has higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.
In the previous week, Microbix Biosystems had 3 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 3 mentions for Microbix Biosystems and 0 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.24 beat Microbix Biosystems' score of 0.00 indicating that Microbix Biosystems is being referred to more favorably in the news media.
Summary
Microbix Biosystems beats BriaCell Therapeutics on 11 of the 14 factors compared between the two stocks.
Get Microbix Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Microbix Biosystems Competitors List
Related Companies and Tools
